

Quellen:

1 LAUER-TAXE® Online 4.0, Stand: Mai 2026

2 GISEA-Register (Iannone et al., J Rheumatol 2012)

3 Hetland et al. (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. *Arthritis Rheum.* 62(1): 22–32

4 Doyle et al. (2013) A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. *BMJ Open.* 3: e001570

5 Favalli et al. (2019) Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. *Arthritis Care Res (Hoboken).* 68(4): 432–439

6 Neovius et al. (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. *Ann Rheum Dis.* 74(2): 354–360

7 Kievit et al. (2008) The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. *Ann Rheum Dis.* 67(9): 1229–1234

8 Strangfeld et al. (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. *Ann Rheum Dis.* 68(12):1856–1862

9 Du Pan et al. (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum.* 61(5): 560–568

10 Marchesoni et al. (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci.* 1173: 837–846

11 Iannone et al. (2012) Longterm retention of tumor necrosis factor- α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. *J Rheumatol.* 39(6): 1179–1184

12 Weinblatt et al. (2011) Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 63(3): 373–382

13 Rahmenvertrag über die Arzneimittelversorgung nach § 129 Absatz 2 SGB V, Stand: April 2026

14 Gebrauchsinformation Enbrel® 25 mg, aktueller Stand

15 Gebrauchsinformation Enbrel® 50 mg, aktueller Stand